RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome Based Upon Learnings From CONNECT-FX (ZYN2-CL-016)

BACKGROUND

- Fragile X syndrome (FXS) is a rare genetic disease caused by alterations of the FMR1 gene and involving a range of developmental, neuropsychiatric, and behavioral symptoms¹
- Patients with complete/nearly complete methylation of their *FMR1* gene are believed most likely to have silencing of their *FMR1* gene^{1,2}
- Current standard of care (including behavioral and educational interventions, dietary modifications, and prescription therapies) has suboptimal efficacy and tolerability^{1,3-6}
- Disruption in the endocannabinoid system is one of the proposed mechanisms for the symptoms observed in FXS,^{7,8} and cannabidiol is a non-psychoactive agent that can regulate this system⁹
- ZYN002 (also known as Zygel[™]) is pharmaceutically produced cannabidiol (not from a plant) that has been uniquely formulated as a gel for transdermal delivery (absorbed through the skin)
- ZYN002 is in clinical development for the treatment of behavioral symptoms associated with FXS, ASD, and 22q11.2 deletion syndrome
- RECONNECT (ZYN2-CL-033) is a pivotal, randomized, double-blind, Phase 3 trial to assess the efficacy and safety of ZYN002 in children and adolescents with FXS aged 3-17 years¹⁰
- RECONNECT is designed based on learnings from CONNECT-FX (ZYN2-CL-016), a randomized, doubleblind, Phase 3 trial completed in 212 patients with FXS during the SARS-CoV-2 (COVID-19) pandemic¹¹

OBJECTIVE

• To describe the learnings from CONNECT-FX, the first randomized, double-blind, placebo-controlled trial of ZYN002 in the treatment of FXS, and how those learnings shaped the design of the follow-on trial, RECONNECT

METHODS

- The primary endpoint in CONNECT-FX was change in severity of Social Avoidance (SA) as measured by the SA subscale of the Aberrant Behavior Checklist-Community FXS (ABC-C_{FXS} SA)
- Secondary endpoints included Caregiver Clinical Global Impression of Change (CaGI-C) for Irritability/Disruptive behaviors and Social Interactions
- A pre-planned ad hoc analysis of patients having ≥90% methylation of the *FMR1* gene was conducted
- A post hoc analysis of patients with complete methylation (100%) of the *FMR1* gene was conducted
- The results and conduct of CONNECT-FX were reviewed to identify key learnings to design RECONNECT


RESULTS

- C_{FXS} SA in the full population but did not reach statistical significance
- In CONNECT-FX, improvements were seen in SA behaviors as measured by ABC-
- Significant improvements were seen in patients with ≥90% or 100% methylation of their *FMR1* gene (**Figure 1A**)
- ZYN002 was superior to placebo in multiple analyses in the groups of patients with either ≥90% methylation or complete methylation (100%, **Figure 1B**) of their *FMR1* gene, which represented 80% and 65% of patients, respectively

Lessons Learned From CONNECT-FX

- their *FMR1* gene
- subscale

Figur	e 1.	СС	ONNE
	Α.	Sig	gnifio
		0.0	+
e a	•	-0.5	-
idance	seline	-1.0	-
ial Avo	Change From Baseline	-1.5	-
	xs occ nge Fro	-2.0	-
	Char	-2.5	-
4	ζ	-3.0	-
		-3.5	



included in the efficacy analysis.

¹Zynerba Pharmaceuticals, Devon, PA, USA; ²The Griesser Group, Conshohocken, PA, USA; ³Labcorp Drug Development., Gaithersburg, MD, USA; ⁴VeraSci, Durham, NC, USA

Treatment response to ZYN002 was greatest in patients with ≥90% methylation of

Qualitative studies¹² support that the ABC-C_{FXS} is fit for purpose in FXS. Meaningful within-patient change thresholds (MCT) were estimated in CONNECT-FX for the SA, Irritability, and Socially Unresponsive/Lethargic subscales¹³

• Caregiver Global Impression of Severity/Change (CaGI-S/C) was responsive to change to treatment with ZYN002, with greatest change on the Social Interactions

• Virtual visits were successfully incorporated as a result of COVID-19 restrictions

^aPrimary endpoint. ^bStatistically significant. LS means. ^cSecondary endpoint. ^dPlacebo n=65, however, 1 patient did not have a post-baseline efficacy measure and was therefore not

Nancy Tich,¹ Terri Sebree,¹ Thomas Dobbins,² Elizabeth Merikle,³ Chris Brady,⁴ Stephen O'Quinn¹

RECONNECT Trial Design Considerations and Trial Design

• Based on learnings from the CONNECT-FX trial, several optimizations were made in the design of the RECONNECT trial (**Table 1** and **Figure 2**)

• Strategic enrichment of the trial population by enrolling a primary group of patients with complete methylation (100%) of their FMR1 gene and a secondary group with partial methylation (<100%) to confirm the impact of *FMR1* methylation on treatment response based upon the data from CONNECT-FX and input from the FDA

• Approximately 160 patients with complete methylation (100%) of *FMR1* will be enrolled

• Approximately 40 patients with partial methylation (<100%) of *FMR1* will be enrolled

• Addition of a third weight-based dose and, in response to FDA guidance, addition of a disease-specific CGI

• The duration of the trial was lengthened from 14 weeks in CONNECT-FX to 18 weeks in RECONNECT to provide more time for assessment of treatment effect

• Other key elements of CONNECT-FX were maintained, including the primary and several key secondary endpoints

Table 1. RECONNECT Trial Design Optimizations

Population enrichment: Patients with complete methylation (100%) of their FMR1 gene as the primary analysis population; patients with partial methylation (<100%) as a secondary group

Dosing: 3 vs 2 weight-based dose strata (250, 500, and 750 mg/day vs 250 and 500 mg/day) incorporated, with the highest dose of 750 mg/day for patients >50 kg to optimize dosing across weight strata

FXS-anchored Clinical Global Impression of Severity/Change (CGI-S/I): Anchored on 3 core behavioral symptoms of FXS: Social Avoidance/Isolation, Social Interactions, and Irritability

Longer trial duration: 18 weeks of treatment vs 14 weeks in CONNECT-FX Virtual visits: Virtual visits incorporated (4 of 8) to reduce burden for families and provide flexibility in the event of ongoing challenges with COVID-19

Figure 2. RECONNECT Trial Design

Trial population

~200 patients with FXS -~160 with complete methylation (100%) of FMR1 3 through 17 years old

18 Weeks of Treatment ZYN002 250, 500, or 750 mg/day* Placebo

Open-label Extension

ZYN002

*Weight-based dosing: ≤30 kg=250 mg/day; >30-50 kg=500 mg/day; >50 kg=750 mg/day.

Endpoints

Primary endpoint

Change from baseline in the ABC- C_{FXS} SA subscale at week 18 in patients with complete methylation (100%) of their *FMR1* gene

Key secondary endpoints

Complete methylation (100%) population

Change from baseline in ABC-C_{FXS} Irritability subscale

Randomized

1:1

- Improvement in CaGI-C Social Interactions
- Improvement in FXS-specific CGI-I
- Change from baseline in ABC-C_{FXS} SA in the full population (complete and
- partial methylation)

CONCLUSIONS

- The design of RECONNECT was optimized from learnings from CONNECT-FX and will provide key data to determine the effectiveness of ZYN002 in FXS, while reducing burden of participation in a clinical trial for families with children and adolescents with FXS
- Results from RECONNECT, if successful, could serve as the basis for ZYN002 approval for use in patients with FXS
- RECONNECT is being conducted in 29 centers in the US, Australia, the UK, and Ireland
- US RECONNECT study locations include:

California Florida Georgia Illinois Maryland Massachusetts

Minnesota Mississippi New Jersey New York North Carolina Ohio

Oklahoma Pennsylvania South Carolina Texas Utah Washington Washington, D.C.

For more information on RECONNECT, visit www.fragilexhelp.com

REFERENCES

- 1. Hagerman RJ, et al. Nat Rev Dis Primers. 2017;3:17065.
- 2. Schneider A, et al. *Transl Psychiatry*. 2020;10(1):205.
- 3. Crawford DC, et al. *Genet Med*. 2001;3(5):359-371.
- . Lozano R, et al. Intractable Rare Dis Res. 2016;5(3):145-157
- 5. Tartaglia N, et al. Cannabis Cannabinoid Res. 2019;4(1):3-
- 6. Heussler H, et al. J Neurodev Disord. 2019;11(1):15.
- 7. Jung KM, et al. *Nat Commun*. 2012;3:1080.
- 8. Busquets-Garcia A, et al. Nat Med. 2013;19(5):603-607.
- 9. Cheung KAK, et al. Front Psychiatry. 2021;12:643442.
- 10.ClinicalTrials.gov. Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome (RECONNECT). NCT04977986. Updated September 16, 2021. Accessed September 18, 2021.
- https://clinicaltrials.gov/ct2/show/NCT04977986 11.ClinicalTrials.gov. Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX). NCT03614663. Updated July 20, 2020. Accessed September 18, 2021.

https://clinicaltrials.gov/ct2/show/NCT03614663 12.Merikle E, et al. Virtual International Society for

- Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Meeting; May 17-20, 2021.
- 13.Merikle E, et al. Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting; April 21-May 1, 2021.

ACKNOWLEDGEMENTS / DISCLOSURES

Acknowledgements

Editorial/medical writing support under the guidance of the authors was provided by *p*-value communications, and was funded by Zynerba Pharmaceuticals, Devon, PA, USA.

Disclosures

NT, TS, and SO are employees of Zynerba Pharmaceuticals. TD is a contractor for Zynerba Pharmaceuticals. EM is an employee of Labcorp Drug Development, which has received research funding from Zynerba. CB is an employee of VeraSci, which has received research funding from Zynerba. The trial was funded by Zynerba Pharmaceuticals.

Presented at the 18th NFXF International Fragile X Conference; July 14-17, 2022; San Diego, California.